rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LEXX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      LEXX: New Pharmaceutical Agreement
      Nov 9Yahoo FinanceLEXX
      Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH
      Nov 4Yahoo FinanceLEXX
      Lexaria Bioscience receives four patents for drug delivery technology
      Oct 28Investing.comLEXX
      Lexaria Celebrates its 70th Patent Award
      Oct 28Yahoo FinanceLEXX
      Lexaria completes enrollment in semaglutide drug delivery study
      Oct 21Investing.comLEXX
      Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
      Oct 21Yahoo FinanceLEXX
      Lexaria Bioscience raises $7.9M, extends cash runway to 2027
      Sep 17Investing.comLEXX
      Lexaria Updates Financial Position

      KELOWNA, BC / ACCESS Newswire / September 17, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.

      Sep 17Yahoo FinanceLEXX
      Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

      KELOWNA, BC / ACCESS Newswire / September 9, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.

      Sep 9Yahoo FinanceLEXX
      LEXX: Introducing DehydraTECH 3.0

      By John Vandermosten, CFA NASDAQ: LEXX READ THE FULL LEXX RESEARCH NOTE Lexaria Bioscience Corp. (NASDAQ: LEXX) announced absorption data from its 2026 Animal Study #2 (GLP-1-A26-2). The canine study examined amycretin and retatrutide bioavailability using oral delivery compared to reference formats. 18 different study arms were evaluated, measuring tablets and capsules as well as DehydraTECH

      Sep 8Yahoo FinanceLEXX
      Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

      KELOWNA, BC / ACCESS Newswire / September 8, 2026 / (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise

      Sep 8Yahoo FinanceLEXX
      Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      KELOWNA, BC / ACCESS Newswire / September 4, 2026 / (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H. Wainwright Global Investment Conference, taking place September 14th through September 16th, 2026 in New York City.

      Sep 4Yahoo FinanceLEXX
      Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs

      Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

      Sep 1The Globe and MailLEXX
      Lexaria Bioscience advances 12% on Australian tax rebate (LEXX:NASDAQ)
      Sep 1Seeking AlphaLEXX
      Lexaria receives $2.6 million Australian R&D tax rebate
      Sep 1Investing.comLEXX
      Lexaria Receives USD$2.6 Million Tax Rebate Payment

      Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebateKELOWNA, BC / ACCESS Newswire / September 1, 2026 / (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.

      Sep 1Yahoo FinanceLEXX
      DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

      At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

      Aug 24Yahoo FinanceLEXX

      This is the newest page. Registered accounts read further back.